The rise of Viagra and its effect on the pharmaceutical landscape presents a complicated question for investors. While the early sales figures were remarkable, the intellectual property has lapsed, leading to a deluge of off-brand alternatives that are chipping away at profit. In addition, the sector is facing difficulties related to population … Read More